Trial Profile

A Long-Term Extension Study Evaluating the Safety and Efficacy of Lorecivivint in Subjects With Osteoarthritis of the Knee

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 31 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Mar 2026 Status changed to discontinued administratively at Visit 6E (Week 100), with no safety concerns, 1 year into the open-label study as described in the protocol. Reason: Study OA-07 was designed to be conducted until the Sponsor closed it.
06 Jan 2026 According to Biosplice Therapeutics media release, company has submitted its NDA to the FDA for approval of Lorecivivint for treatment of knee osteoarthritis.
15 Jun 2024 Results reporting radiographic and pain outcomes, long-term data and repeated usage of Lorecivivint in patients with severe knee osteoarthritis presented at the 25th Annual Congress of the European League Against Rheumatism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com